Home › NDC Lookup › RxCUI directory › RxCUI 1303107

60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza] — RxCUI 1303107

RxNorm drug concept · Semantic branded drug
RxCUI 1303107 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1303107
Official name60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as60 ACTUAT Tudorza 0.4 MG/ACTUAT Dry Powder Inhaler; Tudorza Pressair 400 MCG/INHAL Dry Powder Inhaler, 60 ACTUAT; Tudorza 400 MCG/ACTUAT (aclidinium bromide 375 MCG/ACTUAT from mouthpiece) Dry Powder Inhaler, 60 ACTUAT; Tudorza 400 MCG/ACTUAT Dry Powder Inhaler, 60 ACTUAT
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)2,081 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aclidinium Oral Inhalation: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tudorza Pressair is a maintenance inhaler — meaning you use it every day to help keep your airways relaxed and open, so breathing is easier over time. It's not going to give you in...
  • What exactly is Tudorza Pressair supposed to do for my COPD?
  • No — and this is really important. Tudorza Pressair is not a rescue inhaler. It works too slowly to help in an acute situation. If you're having a sudden flare or breathing emergen...
  • Can I use this if I'm having a sudden breathing attack?
📖 Read our full Aclidinium Oral Inhalation guide →

🕸️ Concept Web — How 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry P... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza] RxCUI 1303107

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Aclidinium 1303098
    • Aclidinium bromide 1303097
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tudorza 1303103
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aclidinium Dry Powder Inhaler 1303101
    • Aclidinium bromide Dry Powder Inhaler 2648844
    • Aclidinium Inhalant Product 1303100
    • Aclidinium bromide Inhalant Product 2663041
    • Aclidinium Dry Powder Inhaler [Tudorza] 1303105
    • Aclidinium bromide Dry Powder Inhaler [Tudorza] 2657306
    • Tudorza Inhalant Product 1303106
    • Dry Powder Inhaler 744995
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler SCD · 1303102
  • Aclidinium bromide 0.4 MG/ACTUAT SCDC · 1303099
  • Aclidinium Dry Powder Inhaler SCDF · 1303101
  • Aclidinium bromide Dry Powder Inhaler SCDFP · 2648844
  • Aclidinium Inhalant Product SCDG · 1303100
  • Aclidinium bromide Inhalant Product SCDGP · 2663041

Brand-Name Concepts

  • Aclidinium bromide 0.4 MG/ACTUAT [Tudorza] SBDC · 1303104
  • Aclidinium Dry Powder Inhaler [Tudorza] SBDF · 1303105
  • Aclidinium bromide Dry Powder Inhaler [Tudorza] SBDFP · 2657306
  • Tudorza Inhalant Product SBDG · 1303106
  • Tudorza BN · 1303103

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 1303107 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70515-0002-01 1 POUCH in 1 CARTON (70515-002-01) / 1 INHALER in 1 POUCH /... Tudorza Pressair Covis Pharma US, Inc 2015-07-01
70515-0002-02 1 POUCH in 1 CARTON (70515-002-02) / 1 INHALER in 1 POUCH /... Tudorza Pressair Covis Pharma US, Inc 2015-07-01
70515-0002-03 1 POUCH in 1 CARTON (70515-002-03) / 1 INHALER in 1 POUCH /... Tudorza Pressair Covis Pharma US, Inc 2015-07-01
Observed labelers: Covis Pharma US, Inc (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$344.3055
Range $257.8000–$430.8110 · middle 50% $301.0528–$387.5583 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.